BDRX — Biodexa Pharmaceuticals Plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1643918 ·
United Kingdom
Last close
$0.68
Market Cap
$699.4K
52W High
$59.40
52W Low
$0.61
ADV30
7,710,694
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 18,179,000 | 8,534,000 | 6,774,000 |
| Jun 2025 | — | — | — | — | 14,824,000 | 4,036,000 | 3,388,000 |
| Dec 2024 | — | — | — | — | 14,780,000 | 1,669,000 | 6,458,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-155,808,000
Inventory
—
Receivables
$222,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,645,000 | -6,384,000 | 18,179,000 | 6,774,000 | 11,405,000 | -5,591,000 |
| Dec 2024 | 0 | -9,199,000 | -5,729,000 | 14,780,000 | 6,458,000 | 8,322,000 | -12,261,000 |
| Dec 2023 | 381,000 | -8,014,000 | -7,079,000 | 10,542,000 | 5,864,000 | 4,678,000 | -6,826,000 |
| Dec 2022 | 699,000 | -8,932,000 | -7,656,000 | 5,525,000 | 2,362,656 | 3,162,344 | -7,048,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.00
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. | $801.5K | $0.10 | — |
| CDT | CDT Equity Inc. | $1.04M | $0.08 | — |
| EVFM | Evofem Biosciences, Inc. | $1.06M | $0.01 | — |
| RGBPP | Regen BioPharma Inc | $460.3K | $0.00 | — |
| SKVI | SKINVISIBLE, INC. | $1.09M | $0.20 | — |
News headlines (Yahoo Finance, 1h cache)
BDRX: Enrollment in Phase 3 SERENTA Trial Reaches 92 Patients
2026-09-22 11:26 · Yahoo
Interim results for the six months ended June 30, 2026
2026-09-11 20:30 · Yahoo
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
2026-08-19 12:30 · Yahoo
Result of Annual General Meeting
2026-06-30 20:30 · Yahoo
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
2026-06-30 12:00 · Yahoo
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
2026-06-29 12:30 · Yahoo
European Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading
2026-09-02 15:13 · Yahoo
BDRX: Expanding Phase 3 SERENTA Trial into Canada; 73 Patients Enrolled Thus Far
2026-06-29 14:17 · Yahoo
The Longview: Fireside Chat with Biodexa CEO Stephen Stamp
2026-09-23 10:30 · Yahoo
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
2026-09-15 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.